Stockscreener 앱 받기
2.55
0.00%
0.00
시간 외 거래:
2.55
전일 마감가:
$2.55
열려 있는:
$2.55
하루 거래량:
428.29K
Relative Volume:
2.12
시가총액:
$74.35M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-1.8997
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
+7.14%
1개월 성능:
+27.50%
6개월 성능:
-15.28%
1년 성능:
-30.33%
1일 변동 폭
$2.50
$2.6732
1주일 범위
$2.25
$2.6732
52주 변동 폭
$1.90
$4.01
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
VTGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.55 | 69.40M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
What analysts say about Vistagen Therapeutics Inc. stockAccelerated investment success - Autocar Professional
Is Vistagen Therapeutics Inc. a good long term investmentHigh-velocity capital appreciation - Autocar Professional
Vistagen Therapeutics Inc. Stock Analysis and ForecastUnmatched profit potential - Autocar Professional
VistaGen Therapeutics (NASDAQ:VTGN) Stock Passes Below 50-Day Moving AverageHere's Why - MarketBeat
What drives Vistagen Therapeutics Inc. stock priceRapid wealth accumulation - jammulinksnews.com
Is Vistagen Therapeutics Inc. stock a good hedge against inflationHigh Confidence Trade Setups - beatles.ru
How Vistagen Therapeutics Inc. stock performs during market volatilityEntry Level Low Risk Picks - Newser
Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser
What makes Vistagen Therapeutics Inc. stock price move sharplyFree Investment Community - Newser
Biotech Leader Vistagen Achieves Rare Double Honor: Mental Health Excellence and Workplace Culture Awards - Stock Titan
Mental Disorder Treatment Market CAGR 28.16% key trends with - openPR.com
Stifel Maintains Buy on Vistagen Therapeutics, Inc. (VTGN) Despite PAL-4 Delay - MSN
Research Analysts Set Expectations for VTGN Q1 Earnings - MarketBeat
Vistagen appoints Elissa Cote as Chief Corporate Development Officer By Investing.com - Investing.com Nigeria
Vistagen (VTGN) Appoints Elissa Cote as Chief Corporate Development Officer | VTGN Stock News - GuruFocus
Vistagen appoints Elissa Cote as Chief Corporate Development Officer - Investing.com
William Blair Issues Negative Forecast for VTGN Earnings - Defense World
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2025 Earnings Call Transcript - Insider Monkey
William Blair Reiterates Outperform Rating for VistaGen Therapeutics (NASDAQ:VTGN) - MarketBeat
Vistagen Therapeutics (VTGN): Can Fasedienol's Phase 3 Success Overcome Financial Strains? - AInvest
Vistagen Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
VistaGen Therapeutics (NASDAQ:VTGN) Receives Outperform Rating from William Blair - Defense World
Stifel reiterates buy rating on VistaGen stock amid clinical progress By Investing.com - Investing.com Canada
Vistagen (VTGN) Advances Fasedienol for Social Anxiety Treatment - GuruFocus
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid ... - Yahoo News Canada
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses - GuruFocus
Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks
Vistagen targets transformative SAD drug approval with top-line PALISADE-3 data in Q4 2025 while advancing differentiated neuroscience pipeline - MSN
Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update - sharewise
Earnings call transcript: Vistagen’s focus on innovation amid rising expenses Q1 2025 - Investing.com India
Vistagen Therapeutics Inc Reports Q1 Revenue of $0.49M, Surpassi - GuruFocus
Vistagen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Vistagen (VTGN) Reports Decrease in FY25 Revenue, Advances Key Medical Programs | VTGN Stock News - GuruFocus
Vistagen Therapeutics, Inc. SEC 10-K Report - TradingView
Vistagen to Report Fiscal Year 2025 Financial Results and Host C - GuruFocus
Vistagen Therapeutics Inc (VTGN) Q4 2025 Earnings Report Preview: What to Look For - GuruFocus
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Holdings Increased by Millennium Management LLC - Defense World
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):